|
4-(Aminosulfonyl)-N-[(2,3,4-Trifluorophenyl)Methyl]-Benzamide
|
DB04549 |
|
|
N-acetyl-N'-beta-D-glucopyranosyl urea
|
DB03218 |
|
|
11-Deoxy-Beta-Rhodomycin
|
DB03219 |
|
|
AME-527
|
DB05879 |
[AME-527 is a humanized monoclonal antibody that recognizes human TNF-alpha (hTNF-alpha) with high affinity and specificity. AME-527 was generated by protein engineering and identified from a library of antibody variants based on its improved binding properties. ] |
|
Inhibitor Bea409
|
DB04547 |
|
|
(1'R,2'S)-9-(2-Hydroxy-3'-Keto-Cyclopenten-1-yl)Adenine
|
DB03216 |
|
|
DPI59
|
DB03217 |
|
|
4-Deoxy-D-Glucuronic Acid
|
DB04548 |
|
|
Afegostat
|
DB04545 |
|
|
Vinylglycine
|
DB03214 |
[Vinylglycine is an irreversible inhibitor of aspartate aminotransferase.] |
|
(2s,5s)-5-Carboxymethylproline
|
DB03215 |
|
|
3-Deaza-Adenosine
|
DB04546 |
|
|
Sar9, Met (O2)11-Substance P
|
DB05875 |
[Sar9, Met (O2)11-Substance P is a neurokinin-1 receptor agonist. It is an analog of the naturally occurring human neuropeptide Substance P, which can be found throughout the body, including in the airways of humans and many other species.] |
|
2,6-Diamino-8-(1h-Imidazol-2-Ylsulfanylmethyl)-3h-Quinazoline-4-One
|
DB04543 |
|
|
4-Deoxyglucarate
|
DB03212 |
|
|
Bis(5-Amidino-2-Benzimidazolyl)Methane Ketone
|
DB03213 |
|
|
1-Deoxy-1-Acetylamino-Beta-D-Gluco-2-Heptulopyranosonamide
|
DB04544 |
|
|
AEOL 10150
|
DB05874 |
[AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants. ] |
|
AVI-4020
|
DB05873 |
[AVI-4020 is a neugene antisense drug candidate for the treatment of patients with acute West Nile virus disease who have serious neurological impairment (WNV neuroinvasive disease).] |
|
(8ar)-Hexahydropyrrolo[1,2-a]Pyrazine-1,4-Dione
|
DB04541 |
|
